Improving patient outcomes in allogeneic HSCT through treosulfan-based conditioning therapy

This activity is older than 12 months.

This patient case series has been developed with the assistance of Prof. Krzysztof Kałwak (Head of the Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University, Poland) and Prof. Arnon Nagler (Director of the Division of Hematology & BMT and Cord Blood Bank at Chaim Sheba Medical Center, Tel-Hashomer, Israel).

The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional license, experience, and knowledge of the individual patient.

For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labelling. Please note that products may have different product labelling according to geographical location. In Europe, full prescribing information is available from the European Medicines Agency (ema.europa.eu).

All characters and events depicted in this patient case simulation are entirely fictitious. Any similarity to actual events or persons, living or dead, is purely coincidental. This activity is intended for a European-based audience, with the potential for global reach of healthcare professionals registered to practise in Europe. To proceed, please confirm that you are a healthcare professional practising in Europe.

Modules

• A 26-month-old girl with acute myeloid leukaemia (AML)

• A 67-year-old man with myelodysplastic syndrome (MDS)